Study tracks combination therapy to treat melanoma

Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances.

Immune cell activity and melanoma

The activity of a certain factor in immune cells is essential for an anti-tumor response, emphasizing the need to consider the effects of anti-cancer therapies on immune cells.

Indiana couple hits the links to support melanoma research

A Vanderbilt-Ingram Cancer Center (VICC) melanoma patient is using his passion for golf to support melanoma research efforts at VICC.

Skin cancer risks higher for soldiers serving abroad

Soldiers deployed to tropical and sunny climates are coming home with increased risk factors for a threat far from the battlefield: skin cancer.

VICC researchers in spotlight at national cancer conference

New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.

Brock family supports promising young researchers